
Abstract

This invention relates to substituted pyridopyrimidinones of general formula (I):



I

wherein

n is 0 to 3;


R^1 and R^2 are, independently, H, C_1-C_6alkyl, hydroxy(C_1-C_6alkyl), formyl, carbonyl(C_1-C_6alkyl), carboxy, or carboxy(C_1-C_6alkyl);

R^3 and R^4 are, independently, H, C_1-C_6alkyl, or hydroxy;

R^{3a} and R^{4a} are H, or one of -CR^3R^{3a} and -CR^4R^{4a} is a carbonyl group;


with the proviso that at least one of the groups R^1 and R^2 must be hydroxy(C_1-C_6alkyl), formyl, carbonyl(C_1-C_6alkyl), carboxy, or carboxy(C_1-C_6alkyl); or one of R^3 and R^4 must be hydroxy; or one of -CR^3R^{3a} and -CR^4R^{4a} must be a carbonyl group; ;

Ar^1 is




wherein W is H, C_1-C_6alkyl, halogen, hydroxy, or C_1-C_6alkoxy;

Ar^2 is



wherein X is



wherein R^5 is H, CH_3, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; or

a tautomer of said compound,

or a pharmaceutically acceptable salt of said compound or tautomer.

The compounds of Formula I are useful for treating hypertension and congestive heart failure. Also disclosed are pharmaceutical compositions containing compounds of Formula I and a pharmaceutically acceptable carrier and methods for production of the compounds of Formula I.

This Sheet Has Been Replaced

